|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
12.12.25 - 07:42
|
Genmab Announces Completion of Tender Offer for Outstanding Common Shares of Merus N.V. and Commencement of Subsequent Offering Period (Business Wire)
|
|
|
Company Announcement
Transaction adds petosemtamab, a late-stage asset with two Breakthrough Therapy Designations, to Genmab's portfolio
Transaction anticipated to be accretive to Genmab's EBITDA by end of 2029
COPENHAGEN, Denmark--(BUSINESS WIRE)--Genmab A/S (Nasdaq: GMAB) (“Genmab”) announced today that the conditions, including the minimum tender condition, to the previously announced tender offer (the “Offer”) by Genmab Holding II B.V., a wholly owned subsidiary of Genmab (“Purchaser”), to acquire all the issued and outstanding common shares of Merus N.V. (Nasdaq: MRUS) (“Merus”) for $97 per common share in cash have been satisfied. The transaction meaningfully accelerates Genmab's shift to a wholly owned model, expanding and diversifying the company's revenue, driving sustained growth into the next decade and contributing to Genmab's evolution into a biotechnology leader.
“The Merus acquisition marks a pivotal step in the delivery of Genmab's long-term strategy and strength...
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Börsentreff auf Facebook |
Börsentreff auf X |
Börsentreff auf Instagram
